The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
| Factor | Score | Distribution | Value | Avg | Verdict |
|---|---|---|---|---|---|
Valuation | 53 | — | 20.3x | Near average | |
Growth | 36 | -74.1% | 5.6% | Near average | |
Quality | 8 | -732.3% | 7.6% | Below average | |
Safety | 36 | 0.2x | 0.4x | Near average | |
Capital Return | 41 | — | 2.15% | Near average | |
Momentum | 0 | — | — | Below average | |
Sentiment | 87 | — | — | Above average |
Ten ratios that matter, each compared against its sector median and average — so you can see whether a number is rich or cheap relative to peers in the same sector.
Aditxt, Inc. (listed on NASDAQ under the ticker ADTX) operates in the biotechnology and immune system health sector, where it focuses on developing technologies aimed at prolonging and monitoring immune system health. The company generates its revenue primarily through providing specialized biotechnology services and products, although it remains in the early stages of commercializing its operations and struggles to achieve sustainable financial stability.
According to the recent quarterly financial data for the first quarter of 2026, the company achieved revenue of $12,159, with a gross profit of $2,868. Despite this slight growth in revenue compared to the fourth quarter of 2025, in which the company recorded revenue of $3,195 and a gross profit of $268, the net loss remained extremely high at -$15.9 million, resulting in a negative earnings per share of -$790.49 per share in the first quarter of 2026.
Aditxt, Inc. stock currently trades at an extremely low market price of $0.0949, placing it at the lower end of its 52-week range of $0.08 to $53,453.52. Considering the analyst consensus, which recommends a 'Buy' with an average price target of $1,280, the stock currently trades significantly below the proposed target, reflecting the large gap between the current valuation and the high operational risks surrounding the company.
In the first quarter of 2026, Aditxt generated revenue of $12,159, which represents an improvement compared to the fourth quarter of 2025 revenue of $3,195. However, these figures remain highly modest and do not cover the company's massive operational costs. It is worth noting that the revenue for the third quarter of 2025 stood at only $748.
Aditxt recorded a net loss of -$15.9 million in the first quarter of 2026, after incurring a net loss of -$43.1 million in the fourth quarter and full fiscal year of 2025. The trailing twelve months (TTM) data shows that the total net losses reached -$49.9 million. These continuous losses lead to a rapid erosion of the company's capital and increase the financial pressures on it.
Yes, biotechnology companies with low market capitalization and low stock prices face increasing pressure to delist from NASDAQ, especially with companies like Rockwell Medical joining the warning list in May 2026. Since ADTX's stock price is currently trading at $0.0949, the risk of delisting remains strongly present unless the company takes corrective measures such as a reverse stock split.
Automated analysis for informational purposes only — not investment advice.
The average price target for Aditxt stock according to analyst consensus is $1,280, which is the same figure set for both the highest and lowest price targets by analysts who recommend a 'Buy'. However, investors must be cautious as the current price of $0.0949 is extremely far from this target, reflecting severe volatility and very high investment risks associated with the company's current financial situation.